DataMeds AI, Inc. (MEDS): Cost of Revenue

Annual figures by period end, from SEC filings.

$29.76M

Year ended 2025-12-31

$15.30M

Trailing 12 months to 2026-06-30

2024-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$29.76M	+81.9%	2026-03-20, From 2025-01-01
2024-12-31	$16.36M	n/a	2026-03-20, From 2024-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Wholesale-Drugs, Proprietaries & Druggists' Sundries), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
DataMeds AI, Inc. (MEDS)	2025-12-31	$29.76M	+81.9%
Cosmos Health Inc. (COSM)	2025-12-31	$57.38M	+14.5%
Stemtech Corp (STEK)	2025-12-31	$566.9K	-57.3%
HWH International Inc. (ESYN)	2025-12-31	$407.2K	-37.5%
Nu Skin Enterprises, Inc. (NUS)	2025-12-31	$453.76M	-17.5%
Herbalife Ltd. (HLF)	2025-12-31	$1.11B	+0.9%
Cardinal Health Inc (CAH)	2026-06-30	$244.47B	+14.0%
Cencora, Inc. (COR)	2025-09-30	$309.85B	+9.1%
McKesson Corp (MCK)	2026-03-31	$388.88B	+12.5%

Compare MEDS, COSM, STEK, ESYN side by side · Screen every company in Wholesale-Drugs, Proprietaries & Druggists' Sundries ↗